- Home
- DBRG vs ANIP Comparison
DBRG vs ANIP Comparison
Compare DBRG & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBRG | ANIP |
|---|---|---|
| Founded | 1991 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | DBRG | ANIP |
|---|---|---|
| Price | $14.42 | $80.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $17.56 | ★ $102.14 |
| AVG Volume (30 Days) | ★ 6.8M | 403.3K |
| Earning Date | 10-30-2025 | 11-07-2025 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.06 | ★ 1.67 |
| Revenue | $100,346,000.00 | ★ $826,880,000.00 |
| Revenue This Year | N/A | $43.41 |
| Revenue Next Year | $191.07 | $9.66 |
| P/E Ratio | $235.07 | ★ $48.00 |
| Revenue Growth | N/A | ★ 48.87 |
| 52 Week Low | $6.41 | $52.50 |
| 52 Week High | $15.55 | $99.50 |
Technical Indicators
Market Signals| Indicator | DBRG | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 68.28 | 34.84 |
| Support Level | $9.44 | $80.30 |
| Resistance Level | $15.55 | $83.60 |
| Average True Range (ATR) | 0.96 | 2.33 |
| MACD | 0.65 | 0.17 |
| Stochastic Oscillator | 81.88 | 25.86 |
Price Performance
Historical ComparisonAbout DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.